SuperGene wires genetic test kits to what happens to patients afterwards — genotype plus real-world data, over time — and turns that loop into intelligence: a model that tells GLP-1 patients and their clinicians what will work.
In development. First launch with our laboratory partner targeted for December 2026.
No one should spend months on a drug that was never going to work for them. The same data engine and validation pipeline extend to the next drug class, and from there toward foundation models of metabolic health.
Two in three patients stop a GLP-1 within a year — cost first, side effects second. A doctor chooses drug, route and titration pace with nothing to say which patient needs which. The signal exists. The record to act on it — genotype plus what happens next, under a prescriber — does not. We are building it.
A start kit before the first dose: the tolerability genes, a flag for rare inherited obesity, a nutrition report and the tracking app. The app and the clinic return what happens next. The model learns from the pool — calibrated odds of side effects, persistence and weight loss — and each followed patient adds an outcome.
Thank you. We read every message and reply from admin@supergene.health.